Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| 9876 | ETCTN | Phase 1b Study of HSP90 Inhibitor, AT13387 (onalespib) in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer. | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9878 | ETCTN | A Phase 1/2 Trial of Erlotinib and Onalespib lactate in EGFR-Mutant Non-Small Cell Lung Cancer | Adult CIRB - Early Phase Emphasis | Completed | |
| 9881 | ETCTN | A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9892 | ETCTN | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9898 | ETCTN | A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9899 | ETCTN | A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Completed | |
| 9903 | ETCTN | A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9910 | ETCTN | A phase 1 trial of MLN0128 (TAK-228) in combination with osimertinib (AZD9291) in advanced EGFR mutation positive non-small cell lung cancer (NSCLC) after progression on a previous EGFR tyrosine kinase inhibitor | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9914 | ETCTN | A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors | Adult CIRB - Early Phase Emphasis | Completed | |
| 9922 | ETCTN | A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance | Adult CIRB - Early Phase Emphasis | Completed |